Literature DB >> 30882996

Anatomical, histomorphological and molecular classification of cholangiocarcinoma.

Timothy Kendall1, Joanne Verheij2, Eugenio Gaudio3, Matthias Evert4, Maria Guido5, Benjamin Goeppert6, Guido Carpino7.   

Abstract

Cholangiocarcinoma constitutes a heterogeneous group of malignancies that can emerge at any point of the biliary tree. Cholangiocarcinoma is classified into intrahepatic, perihilar and distal based on its anatomical location. Histologically, conventional perihilar/distal cholangiocarcinomas are mucin-producing adenocarcinomas or papillary tumours; intrahepatic cholangiocarcinomas are more heterogeneous and can be sub-classified according to the level or size of the displayed bile duct. Cholangiocarcinoma develops through multistep carcinogenesis and is preceded by dysplastic and in situ lesions. Definition and clinical significance of precursor lesions, including biliary intraepithelial neoplasia, intraductal papillary neoplasms of the bile duct, intraductal tubulopapillary neoplasms and mucinous cystic neoplasm, are discussed in this review. A main challenge in diagnosing cholangiocarcinoma is the fact that tumour tissue for histological examination is difficult to obtain. Thus, a major clinical obstacle is the establishment of the correct diagnosis at a tumour stage that is amenable to surgery which still represents the only curable therapeutic option. Current standards, methodology and criteria for diagnosis are discussed. Cholangiocarcinoma represents a heterogeneous tumour with regard to molecular alterations. In intrahepatic subtype, mainly two distinctive morpho-molecular groups can currently be discriminated. Large-duct type intrahepatic cholangiocarcinoma shows a high mutation frequency of oncogenes and tumour suppressor genes, such as KRAS and TP53 while Isocitrate Dehydrogenase 1/2 mutations and Fibroblast Growth Factor Receptor 2-fusions are typically seen in small-duct type tumours. It is most important to ensure the separation of the given anatomical subtypes and to search for distinct subgroups within the subtypes on a molecular and morphological basis.
© 2019 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  cholangiocarcinoma; diagnosis; molecular profile; preneoplastic lesion

Mesh:

Substances:

Year:  2019        PMID: 30882996     DOI: 10.1111/liv.14093

Source DB:  PubMed          Journal:  Liver Int        ISSN: 1478-3223            Impact factor:   5.828


  59 in total

1.  NUC-1031 in biliary tract cancer: from bench to bedside and back?

Authors:  Lenka N C Boyd; Godefridus J Peters; Geert Kazemier; Elisa Giovannetti
Journal:  Cancer Chemother Pharmacol       Date:  2020-05-31       Impact factor: 3.333

Review 2.  Cholangiocarcinoma 2020: the next horizon in mechanisms and management.

Authors:  Jesus M Banales; Jose J G Marin; Angela Lamarca; Pedro M Rodrigues; Shahid A Khan; Lewis R Roberts; Vincenzo Cardinale; Guido Carpino; Jesper B Andersen; Chiara Braconi; Diego F Calvisi; Maria J Perugorria; Luca Fabris; Luke Boulter; Rocio I R Macias; Eugenio Gaudio; Domenico Alvaro; Sergio A Gradilone; Mario Strazzabosco; Marco Marzioni; Cédric Coulouarn; Laura Fouassier; Chiara Raggi; Pietro Invernizzi; Joachim C Mertens; Anja Moncsek; Sumera Rizvi; Julie Heimbach; Bas Groot Koerkamp; Jordi Bruix; Alejandro Forner; John Bridgewater; Juan W Valle; Gregory J Gores
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2020-06-30       Impact factor: 46.802

Review 3.  Imaging mimickers of cholangiocarcinoma: a pictorial review.

Authors:  Si Min Chiow; Hau Wei Khoo; Jee Keem Low; Cher Heng Tan; Hsien Min Low
Journal:  Abdom Radiol (NY)       Date:  2022-01-03

4.  Utility of DNA flow cytometry in distinguishing between malignant and benign intrahepatic biliary lesions.

Authors:  Kwun Wah Wen; Peter S Rabinovitch; Dongliang Wang; Aras N Mattis; Linda D Ferrell; Won-Tak Choi
Journal:  Virchows Arch       Date:  2020-04-15       Impact factor: 4.064

Review 5.  Intrahepatic cholangiocarcinoma: Morpho-molecular pathology, tumor reactive microenvironment, and malignant progression.

Authors:  Alphonse E Sirica; Mario Strazzabosco; Massimiliano Cadamuro
Journal:  Adv Cancer Res       Date:  2020-12-09       Impact factor: 6.242

Review 6.  Cholangiocarcinoma: bridging the translational gap from preclinical to clinical development and implications for future therapy.

Authors:  Leonardo Baiocchi; Keisaku Sato; Burcin Ekser; Lindsey Kennedy; Heather Francis; Ludovica Ceci; Ilaria Lenci; Domenico Alvaro; Antonio Franchitto; Paolo Onori; Eugenio Gaudio; Chaodong Wu; Sanjukta Chakraborty; Shannon Glaser; Gianfranco Alpini
Journal:  Expert Opin Investig Drugs       Date:  2020-12-08       Impact factor: 6.206

Review 7.  Recent Advances in Implantation-Based Genetic Modeling of Biliary Carcinogenesis in Mice.

Authors:  Masashi Izumiya; Shingo Kato; Yoshitaka Hippo
Journal:  Cancers (Basel)       Date:  2021-05-11       Impact factor: 6.639

Review 8.  Biomarkers in Hepatobiliary Cancers: What is Useful in Clinical Practice?

Authors:  Alice Boilève; Marc Hilmi; Matthieu Delaye; Annemilaï Tijeras-Raballand; Cindy Neuzillet
Journal:  Cancers (Basel)       Date:  2021-05-30       Impact factor: 6.639

Review 9.  Liquid biopsy in cholangiocarcinoma: Current status and future perspectives.

Authors:  Gianluca Rompianesi; Marcello Di Martino; Alex Gordon-Weeks; Roberto Montalti; Roberto Troisi
Journal:  World J Gastrointest Oncol       Date:  2021-05-15

10.  A Study on Mesoporous Silica Loaded With Novel Photosensitizers HCE6 and Oxaliplatin for the Treatment of Cholangiocarcinoma.

Authors:  Pei-Jian Zhang; Meng-Dong Liu; Fang-Yong Fan; Ke-Xia Liu
Journal:  Front Oncol       Date:  2021-06-29       Impact factor: 6.244

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.